title: How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.
authors: Department of Microbiology, Immunology and Infectious Diseases, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada, joelle.st-pierre@ucalgary.ca.
authors: Joëlle
authors: J
authors: St-Pierre
authors: Kris
authors: K
authors: Chadee
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D005762:Gastroenterology / Q000266:history; D005765:Gastrointestinal Agents / Q000266:history; D049673:History, 20th Century; D006801:Humans; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000266:history
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab